CY1124719T1 - Τοπικη συνθεση η οποια περιλαμβανει καλσιποτριολη και διπροπιονικη βηταμεθαζονη - Google Patents

Τοπικη συνθεση η οποια περιλαμβανει καλσιποτριολη και διπροπιονικη βηταμεθαζονη

Info

Publication number
CY1124719T1
CY1124719T1 CY20211100971T CY211100971T CY1124719T1 CY 1124719 T1 CY1124719 T1 CY 1124719T1 CY 20211100971 T CY20211100971 T CY 20211100971T CY 211100971 T CY211100971 T CY 211100971T CY 1124719 T1 CY1124719 T1 CY 1124719T1
Authority
CY
Cyprus
Prior art keywords
betamethasone dipropionate
composition containing
topical composition
containing calcipotriol
calcipotriol
Prior art date
Application number
CY20211100971T
Other languages
English (en)
Inventor
Nigel Crutchley
Michelle Georgiou
Stephen Lenon
Morten Praestegaard
Original Assignee
MC2 Therapeutics Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MC2 Therapeutics Limited filed Critical MC2 Therapeutics Limited
Publication of CY1124719T1 publication Critical patent/CY1124719T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια σύνθεση για τοπική εφαρμογή, η οποία περιλαμβάνει μια διασπορά polyaphron, όπου η διασπορά polyaphron που περιλαμβάνει μια συνεχή υδατική φάση και τουλάχιστον μια ασυνεχή ελαιώδη φάση, όπου η διασπορά polyaphron περιλαμβάνει καλσιποτριόλη, διπροπιονική βηταμεθαζόνη, άλφα-τοκοφερόλη και βουτυλίωμένη υδροξυανισόλη, και όπου η σύνθεση έχει pΗ 7,75 ± 0,5.
CY20211100971T 2018-03-19 2021-11-09 Τοπικη συνθεση η οποια περιλαμβανει καλσιποτριολη και διπροπιονικη βηταμεθαζονη CY1124719T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18162664.9A EP3542788A1 (en) 2018-03-19 2018-03-19 Topical composition comprising calcipotriol and betamethasone dipropionate
PCT/EP2019/056735 WO2019179958A1 (en) 2018-03-19 2019-03-18 Topical composition

Publications (1)

Publication Number Publication Date
CY1124719T1 true CY1124719T1 (el) 2022-07-22

Family

ID=61691823

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100971T CY1124719T1 (el) 2018-03-19 2021-11-09 Τοπικη συνθεση η οποια περιλαμβανει καλσιποτριολη και διπροπιονικη βηταμεθαζονη

Country Status (23)

Country Link
US (2) US11696919B2 (el)
EP (3) EP3542788A1 (el)
JP (2) JP2021518409A (el)
KR (2) KR20230172042A (el)
CN (2) CN113499343B (el)
AU (1) AU2019239544B2 (el)
BR (1) BR112020019075A2 (el)
CA (1) CA3093999A1 (el)
CY (1) CY1124719T1 (el)
DK (1) DK3768241T3 (el)
ES (1) ES2896931T3 (el)
HR (1) HRP20211759T1 (el)
HU (1) HUE056223T2 (el)
IL (1) IL277213B1 (el)
LT (1) LT3768241T (el)
MX (1) MX2020009764A (el)
PH (1) PH12020551467A1 (el)
PL (1) PL3768241T3 (el)
PT (1) PT3768241T (el)
RS (1) RS62492B1 (el)
SG (1) SG11202008698QA (el)
SI (1) SI3768241T1 (el)
WO (1) WO2019179958A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201701583D0 (en) 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
CN113092601B (zh) * 2021-03-02 2022-12-20 苏州市药品检验检测研究中心 一种化妆品中倍他米松17-丙酸酯及倍他米松21-丙酸酯的检测方法

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486333A (en) 1981-04-10 1984-12-04 Felix Sebba Preparation of biliquid foam compositions
JPS59222409A (ja) 1983-06-01 1984-12-14 Nippon Redarii Kk 消炎鎮痛ゲル軟膏剤
CA1272953A (en) 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
JPH07553B2 (ja) 1985-12-09 1995-01-11 佐藤製薬株式会社 フイルム状製剤
ZA888819B (en) 1987-12-02 1990-07-25 Ici Australia Operations Process for preparing explosive
US4900552A (en) 1988-03-30 1990-02-13 Watson Laboratories, Inc. Mucoadhesive buccal dosage forms
US4944938A (en) 1988-12-16 1990-07-31 Colgate-Palmolive Company Antiperspirant and deodorant
US4999198A (en) 1989-03-23 1991-03-12 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Polyaphrons as a drug delivery system
US5185150A (en) 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
DE69125230T2 (de) 1990-09-04 1997-07-10 Fujisawa Pharmaceutical Co Tricyclische Verbindungen enthaltende Salben
ATE173401T1 (de) 1990-09-07 1998-12-15 Wisconsin Alumni Res Found Neue verwendung von 1-alpha-hydroxylierten-19-nor-vitamin-d-verbind ngen zur behandlung von psoriasis
US5840881A (en) 1992-11-27 1998-11-24 Takeda Chemical Industries, Ltd. Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility
US5763426A (en) 1993-01-15 1998-06-09 Leo Pharmaceutical Products Ltd. Crystalline form of a vitamin D analogue
FR2710840B1 (fr) 1993-10-04 1995-12-01 Applic Transferts Technolo Compositions viscoélastiques hautement concentrées en composés fluorés, leur préparation et leurs utilisations dans le domaine médical et en cosmétique.
US5549888A (en) 1994-01-31 1996-08-27 Procter & Gamble Aqueous topical anti-acne compositions of low pH
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
FR2719220A1 (fr) 1994-04-29 1995-11-03 Lafon Labor Nouvelle forme galénique pour l'administration transdermique.
US6538039B2 (en) 1994-04-29 2003-03-25 Laboratoire L. Lafon Pharmaceutical dosage form for transdermal administration
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
IL110117A0 (en) 1994-06-24 1994-10-07 Univ Ben Gurion Pharmaceutical compositions comprising vitamin-d analogs
AU714254B2 (en) 1994-10-26 1999-12-23 Novartis Ag Pharmaceutical compositions
KR0159145B1 (ko) 1995-02-24 1998-12-01 강박광 피부 약물 전달 체계용 에멀젼 네트웍의 제조방법
US6238678B1 (en) 1995-11-06 2001-05-29 The Procter & Gamble Company Methods of regulating skin appearance with vitamin B3 compound
EP0884995B1 (en) 1996-03-08 2002-06-05 Disperse Limited Dispersions comprising an oil-based biliquid foam and an aqueous gel
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
KR100471341B1 (ko) 1996-05-23 2005-07-21 제네시스 테크놀로지 가부시키가이샤 콘택트프로브및그것을구비한프로브장치
NL1003503C2 (nl) 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
US5800832A (en) 1996-10-18 1998-09-01 Virotex Corporation Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
US5955097A (en) 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
JPH10139669A (ja) 1996-11-05 1998-05-26 Teijin Ltd 脂漏性角化症治療剤
GB2326337A (en) 1997-06-20 1998-12-23 Phares Pharma Holland Homogeneous lipid compositions for drug delivery
ATE497384T1 (de) 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US5990100A (en) 1998-03-24 1999-11-23 Panda Pharmaceuticals, L.L.C. Composition and method for treatment of psoriasis
ES2237104T3 (es) 1998-04-29 2005-07-16 Virotex Corporation Dispositivo portador de productos farmaceuticos adecuado para el aporte de compuestos farmaceuticos a superficies mucosas.
GB9814640D0 (en) 1998-07-06 1998-09-02 Fujisawa Pharmaceutical Co New use
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
IL145983A0 (en) 1999-04-23 2002-07-25 Leo Pharm Prod Ltd Pharmaceutical composition for dermal use, comprising a corticosteroid and a vitamin d or an analogue thereof
US6200581B1 (en) 1999-04-28 2001-03-13 Dow Corning Corporation Elastomeric silicone terpolymer
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
DE60105362T2 (de) 2000-02-22 2005-02-17 Color Access, Inc. Wässrige kosmetische gele
AU7323001A (en) 2000-07-07 2002-01-21 Av Topchiev Inst Petrochemical Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
MXPA03003511A (es) 2000-10-27 2004-05-04 Leo Pharma As Composicion topica que contiene al menos una vitamina d o un analogo de vitamina de y al menos un corticosteroide.
RU2276177C2 (ru) 2001-05-01 2006-05-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Российской Академии Наук Получение гидрофильных, чувствительных к давлению адгезивов с оптимизированными адгезионными свойствами
BR0210013A (pt) 2001-05-25 2004-08-10 Valley Forge Pharmaceuticals Gel oftálmico de pirenzepina
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7415169B2 (en) 2001-11-30 2008-08-19 Koninklijke Philips Electronics N.V. Medical viewing system and method for enhancing structures in noisy images
GB0202312D0 (en) 2002-01-31 2002-03-20 Disperse Technologies Plc Polyaphron fuel compositions
GB0214793D0 (en) 2002-06-26 2002-08-07 Disperse Technologies Plc Biliquid foam entrapment
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7053124B2 (en) 2002-11-06 2006-05-30 Disperse Limited Aerosol delivery systems
US20050026877A1 (en) 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
GB0307866D0 (en) 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20050020546A1 (en) 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
WO2005001643A2 (en) 2003-06-21 2005-01-06 J Maev Jack Ivan Method and apparatus for encouraged visitation web advertising
FR2856301B1 (fr) 2003-06-23 2007-08-03 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
DE602004025929D1 (de) 2003-07-01 2010-04-22 Skinsure Internat Ltd Barriereformulierung mit einer emulsion auf silikonbasis
CA2530843A1 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
GB0317868D0 (en) 2003-07-30 2003-09-03 Disperse Ltd Biliquid foams with a high alcohol content and products formulated therefrom
GB0317869D0 (en) 2003-07-30 2003-09-03 Disperse Ltd Improved drug delivery system
CA2535846A1 (en) 2003-08-15 2005-02-24 Qlt Usa, Inc. Adhesive bioerodible transmucosal drug delivery system
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
JP2005123083A (ja) 2003-10-17 2005-05-12 Dainippon Screen Mfg Co Ltd 塗布組成物および有機ｅｌ素子の製造方法
CA2543577A1 (en) 2003-11-21 2005-06-16 Galderma Research & Development, S.N.C. Sprayable composition for the administration of vitamin d derivatives
FR2862540B1 (fr) 2003-11-21 2007-03-30 Galderma Res & Dev Composition sous forme de spray comprenant un actif pharmaceutique, au moins un silicone volatile et une phase non polaire non volatile
GB0401101D0 (en) 2004-01-19 2004-02-18 Disperse Ltd Dispersions
GB0404403D0 (en) 2004-02-27 2004-03-31 Disperse Ltd Dispersions
US20050249757A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical cream formulations
FR2871694B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
FR2871696B1 (fr) 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis
FR2871700B1 (fr) 2004-06-17 2006-11-17 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, et une phase huileuse
FR2871697B1 (fr) 2004-06-17 2007-06-29 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques, une phase alcoolique, au moins un silicone volatile et une phase huileuse non volatile
SI1771180T2 (sl) 2004-06-17 2011-02-28 Galderma Sa Zmes v obliki pršila, ki vsebuje kombinacijo klobetazol propionata in kalcitrola, alkoholna faza in oljna faza
FR2871695B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un agent silicone et deux principes actifs solubilises
AU2005253733A1 (en) 2004-06-17 2005-12-29 Galderma S.A. Composition in spray form comprising a combination of a corticoid and a vitamin D derivative in an oily phase
FR2871693B1 (fr) 2004-06-17 2006-08-25 Galderma Sa Utilisation d'une composition pharmaceutique comprenant du calcitriol et du propionate de clobetasol pour le traitement du psoriasis
FR2871698B1 (fr) 2004-06-17 2008-07-04 Galderma Sa Composition sous forme de spray comprenant une association d'actifs pharmaceutiques et une phase huileuse
FR2871699A1 (fr) 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
EP1758589A1 (en) 2004-06-17 2007-03-07 Galderma S.A. Composition for the treatment of psoriasis comprising a silicone agent, a corticosteroid and vitamin d or a derivative thereof
IT1333365B1 (it) 2004-09-09 2006-04-11 Alberto Fiorenzi Apparecchiatura e procedimento per realizzare una vela e relativa vela realizzata
WO2006050837A2 (en) 2004-11-09 2006-05-18 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressive agent
KR100678829B1 (ko) 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
ZA200706455B (en) * 2005-01-05 2009-02-25 Novacea Inc Prevention of thrombotic disorders with active vitamin D compounds or mimics thereof
CN101203198A (zh) 2005-03-14 2008-06-18 马克罗化学公司 大环内酯通过人皮肤渗透的增强
WO2006111426A1 (en) 2005-04-19 2006-10-26 Galderma S.A. Composition of film-forming solution type, comprising vitamin d or a derivative thereof and a corticosteroid, and use thereof in dermatology
GB0508827D0 (en) 2005-04-29 2005-06-08 Novartis Ag Cosmeceutical composition
PL1917072T3 (pl) 2005-06-01 2014-01-31 Glaxosmithkline Ip Dev Ltd Formulacja witaminowa
FR2889662B1 (fr) 2005-08-11 2011-01-14 Galderma Res & Dev Emulsion de type huile-dans-eau pour application topique en dermatologie
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
KR100658436B1 (ko) 2005-12-09 2006-12-27 한국화학연구원 아데노실코발라민 함유 피부질환 치료용 외용제 조성물
DK1988779T5 (en) 2006-02-16 2016-10-10 Anacor Pharmaceuticals Inc SMALL boron MOLECULES AS ANTI-INFLAMMATORY AGENTS
WO2007120910A1 (en) 2006-04-14 2007-10-25 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The Univ. Of Nevada, Reno Arsenic absorbing composition and methods of use
US8188052B2 (en) 2006-05-19 2012-05-29 Scynexis, Inc. Method for the treatment and prevention of ocular disorders
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2670425A1 (en) 2006-08-29 2008-03-06 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions including vitamin d and corticosteroid
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP1970049A1 (en) 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D and corticosteroid
EP1970047A1 (en) 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with a corticosteroid
EP1970048A1 (en) 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
GB0712389D0 (en) 2007-06-26 2007-08-01 Drug Delivery Solutions Ltd A Pharmaceutical composition
CA2730221C (en) 2007-07-09 2016-02-02 Novagali Pharma Sa Oil in water emulsion comprising nsaids and quaternary ammonium halides
US8412809B2 (en) 2007-10-24 2013-04-02 International Business Machines Corporation Method, apparatus and computer program product implementing multi-tenancy for network monitoring tools using virtualization technology
US8623852B2 (en) 2007-12-04 2014-01-07 Santen Sas Topical methods and compositions for the treatment of eye diseases and conditions
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
MX2010009765A (es) 2008-03-06 2013-07-12 Anacor Pharmaceuticals Inc Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
AU2010217190B2 (en) 2009-02-25 2012-10-25 Mayne Pharma Llc Topical foam composition
US20110009339A1 (en) 2009-04-14 2011-01-13 Allergan, Inc Method of treating blurred vision and other conditions of the eye with cyclosporin compositions
US20100272875A1 (en) 2009-04-24 2010-10-28 Monsanto Technology Llc Omega-3 enriched cereal, granola, and snack bars
WO2010127301A1 (en) 2009-05-01 2010-11-04 Allergan, Inc. Method of treating allergic conjunctivitis with cyclosporin compositions
CA2761039A1 (en) * 2009-05-07 2010-11-11 Tolmar, Inc. Pharmaceutical composition including a corticosteroid and a vitamin d analog having improved stability
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
DK2473161T3 (en) 2009-08-31 2017-09-11 Dr Reddys Laboratories Ltd TOPICAL FORMULATIONS INCLUDING A STEROID
EP2308468A1 (en) 2009-10-08 2011-04-13 Novaliq GmbH Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
ES2591352T3 (es) 2010-02-17 2016-11-28 Veloxis Pharmaceuticals A/S Composición de tacrolimus estabilizada
US8784780B2 (en) * 2010-06-11 2014-07-22 Precision Dermatology, Inc. High oil-content emollient aerosol foam compositions
SI2579852T1 (sl) 2010-06-11 2015-03-31 Leo Pharma A/S Farmacevtski sprej sestavek obsegajoäś vitamin d analog in kortikosteroid
WO2012011192A1 (ja) 2010-07-23 2012-01-26 マルホ株式会社 タクロリムスを含有する水中油型クリーム状組成物
US9610245B2 (en) 2011-03-14 2017-04-04 Drug Delivery Solutions Limited Ophthalmic composition
NZ742208A (en) 2015-11-30 2023-03-31 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
AU2017247963B2 (en) 2016-04-04 2022-10-20 Drug Delivery Solutions Limited Topical composition comprising tacrolimus
MX2018014485A (es) 2016-05-25 2019-08-12 Glenmark Pharmaceuticals Ltd Composiciones topicas estables de luliconazol.
CN108815174A (zh) * 2018-05-25 2018-11-16 昆山普瑞凯纳米技术有限公司 一种改良型脂溶性组合物及其制备方法

Also Published As

Publication number Publication date
JP2023126762A (ja) 2023-09-12
AU2019239544A1 (en) 2020-10-08
IL277213A (en) 2020-10-29
RU2020133965A (ru) 2022-04-19
BR112020019075A2 (pt) 2020-12-29
CA3093999A1 (en) 2019-09-26
CN113499343A (zh) 2021-10-15
US20230226077A1 (en) 2023-07-20
LT3768241T (lt) 2021-11-25
EP3542788A1 (en) 2019-09-25
EP3925600A1 (en) 2021-12-22
KR20230172042A (ko) 2023-12-21
SI3768241T1 (sl) 2022-01-31
DK3768241T3 (da) 2021-11-01
SG11202008698QA (en) 2020-10-29
PL3768241T3 (pl) 2022-01-17
MX2020009764A (es) 2020-10-08
WO2019179958A1 (en) 2019-09-26
KR20200135400A (ko) 2020-12-02
PH12020551467A1 (en) 2021-09-01
KR102614025B1 (ko) 2023-12-14
IL277213B1 (en) 2024-04-01
US20210015831A1 (en) 2021-01-21
HRP20211759T1 (hr) 2022-02-18
EP3768241A1 (en) 2021-01-27
AU2019239544B2 (en) 2024-02-22
RS62492B1 (sr) 2021-11-30
CN111867563A (zh) 2020-10-30
PT3768241T (pt) 2021-11-04
US11696919B2 (en) 2023-07-11
ES2896931T3 (es) 2022-02-28
JP2021518409A (ja) 2021-08-02
CN113499343B (zh) 2023-07-21
EP3768241B1 (en) 2021-09-08
HUE056223T2 (hu) 2022-02-28

Similar Documents

Publication Publication Date Title
CY1124719T1 (el) Τοπικη συνθεση η οποια περιλαμβανει καλσιποτριολη και διπροπιονικη βηταμεθαζονη
CO2018008754A2 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
CO2022010098A2 (es) Inhibidores de proteínas kras mutantes
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2016000221A1 (es) Anticuerpos anti-fgfr2iiib afucosilados.
BR112018001381A2 (pt) material lubrificante para auxiliar um processo de usinagem e método de usinagem
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
CY1124427T1 (el) Συνθεση omecamtiv mecarbil
CY1124338T1 (el) Αναστολεις 3-φωσφογλυκερικης αφυδρογονασης και χρησεις αυτων
CR20190387A (es) Anticuerpos contra triptasa, composiciones de estos y usos de estos
AR098168A1 (es) Formulación estable de insulina glulisina
EA202192146A1 (ru) Антитела к клаудину 6 и их применение
BR112018003267A2 (pt) chapa de aço
BR112017022971A2 (pt) aperfeiçoamentos em ou com relação a compostos orgânicos
BR112019003725A2 (pt) composição de antiperspirante ou desodorante
WO2019051327A3 (en) BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
BR112015011515A2 (pt) Composições farmacêuticas de inibidores de cetp
BR112018014884A2 (pt) produto para lavagem de roupas e pastilha
CL2016003155A1 (es) Composiciones de cuidado bucal
AR106981A1 (es) Una composición antimicrobiana
CO2020015124A2 (es) Anticuerpo anti-tlr7 humano
BR112017016056A2 (pt) métodos para modificar uma configuração e auxiliar um dispositivo sem fio a modificar uma configuração, dispositivo sem fio, nó de rede, programa de computador, e, portadora.
BR112017015740B8 (pt) Composições de fragrâncias e dispositivos para cuidados do ar